On the clinical relevance of using complete high-resolution HLA typing for an accurate interpretation of posttransplant immune-mediated graft outcomes
| العنوان: | On the clinical relevance of using complete high-resolution HLA typing for an accurate interpretation of posttransplant immune-mediated graft outcomes |
|---|---|
| المؤلفون: | Meneghini, Maria, Perona, Anna, Crespo, Elena, Bemelman, Frederike, Reinke, Petra, Viklicky, Ondrej, Giral, Magali, Palou, Eduard, Torija, Alba, Donadeu, Laura, Melilli, Edoardo, Zuñiga, Jose, Sefrin, Anett, Lachmann, Nils, Hu, Liu, Hruba, Petra, Guillot-Gueguen, C. cile, Brouard, Sophie, Grinyo, Josep, Bestard, Oriol |
| المساهمون: | Institut Català de la Salut, [Meneghini M, Bestard O] Unitat de Trasplantament Hepàtic, Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Perona A] Department of Medicine, Barcelona University, Barcelona, Spain. [Crespo E, Torija A, Donadeu L] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Bemelman F] Renal Transplant Unit, Department of Internal Medicine, Amsterdam University Medical Centers, Academic Medical Center - University of Amsterdam, Amsterdam, Netherlands. [Reinke P] Berlin Center for Advanced Therapies (BeCAT), Berlin Institute of Health Center for Regenerative Therapies (BCRT) and Department of Nephrology and Intensive Care, Charité Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany. [Viklicky O] Transplant Laboratory, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czechia. Department of Nephrology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czechia. [Zuñiga J] Unitat de Trasplantament Hepàtic, Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron University Hospital [Barcelona], Universitat Autònoma de Barcelona (UAB), University of Barcelona, University of Amsterdam [Amsterdam] (UvA), Berlin Institute of Health (BIH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Transplant laboratory [Prague, Czech Republic], Institute for Clinical and Experimental Medicine (IKEM), Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) (U1064 Inserm - CR2TI), Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology (U1064 Inserm - CR2TI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] (ITERT), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Clinic Barcelona Hospital Universitari, KERANDEL-DION, Céline, Nephrology, AII - Inflammatory diseases, APH - Aging & Later Life |
| المصدر: | Scientia Frontiers in Immunology Frontiers in Immunology, 2022, 13, pp.924825. ⟨10.3389/fimmu.2022.924825⟩ Frontiers in immunology, 13:924825. Frontiers Media S.A. |
| بيانات النشر: | Frontiers Media SA, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Empelt contra l'hoste, Malaltia de l', Biological Factors::Antigens::Antigens, Surface::Histocompatibility Antigens::HLA Antigens [CHEMICALS AND DRUGS], Graft Rejection, [SDV]Life Sciences [q-bio], precision medicine, Immunology, Trasplantament renal, kidney transplantation, HLA-C Antigens, Immune System Phenomena::Transplantation Immunology::Host vs Graft Reaction::Graft Rejection [PHENOMENA AND PROCESSES], donor-specific antibodies, Kidney transplantation, Antígens HLA, HLA Antigens, Humans, Immunology and Allergy, Histocompatibilitat - Proves, kidney transplantation HLA typing donor-specific antibodies allograft rejection precision medicine, allograft rejection, Histocompatibility Testing, Graft Survival, factores biológicos::antígenos::antígenos de superficie::antígenos de histocompatibilidad::antígenos HLA [COMPUESTOS QUÍMICOS Y DROGAS], diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::pruebas inmunológicas::pruebas de histocompatibilidad [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], [SDV] Life Sciences [q-bio], Rebuig (Biologia), HLA typing, Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Immunologic Tests::Histocompatibility Testing [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Graft rejection, fenómenos del sistema inmunitario::inmunología del trasplante::reacción huésped contra injerto::rechazo del injerto [FENÓMENOS Y PROCESOS] |
| الوصف: | HLA typing; Donor-specific antibodies; Kidney transplantation Tipificación de HLA; Anticuerpos específicos del donante; Trasplante de riñón Tipificació de HLA; Anticossos específics del donant; Trasplantament de ronyó Complete and high-resolution (HR) HLA typing improves the accurate assessment of donor–recipient compatibility and pre-transplant donor-specific antibodies (DSA). However, the value of this information to identify de novo immune-mediated graft events and its impact on outcomes has not been assessed. In 241 donor/recipient kidney transplant pairs, DNA samples were re-evaluated for six-locus (A/B/C/DRB1/DQB1+A1/DPB1) HR HLA typing. De novo anti-HLA antibodies were assessed using solid-phase assays, and dnDSA were classified either (1) as per current clinical practice according to three-locus (A/B/DRB1) low-resolution (LR) typing, estimating donor HLA-C/DQ typing with frequency tables, or (2) according to complete six-locus HR typing. The impact on graft outcomes was compared between groups. According to LR HLA typing, 36 (15%) patients developed dnDSA (LR_dnDSA+). Twenty-nine out of 36 (80%) were confirmed to have dnDSA by HR typing (LR_dnDSA+/HR_dnDSA+), whereas 7 (20%) did not (LR_dnDSA+/HR_dnDSA−). Out of 49 LR_dnDSA specificities, 34 (69%) were confirmed by HR typing whereas 15 (31%) LR specificities were not confirmed. LR_dnDSA+/HR_dnDSA+ patients were at higher risk of ABMR as compared to dnDSA− and LR_dnDSA+/HR_dnDSA− (logRank < 0.001), and higher risk of death-censored graft loss (logRank = 0.001). Both LR_dnDSA+ (HR: 3.51, 95% CI = 1.25–9.85) and LR_dnDSA+/HR_dnDSA+ (HR: 4.09, 95% CI = 1.45–11.54), but not LR_dnDSA+/HR_dnDSA− independently predicted graft loss. The implementation of HR HLA typing improves the characterization of biologically relevant de novo anti-HLA DSA and discriminates patients with poorer graft outcomes. This work was supported by the Biomarker-Driven Immunosuppression Minimization (BIO-DRIM) Consortium (EU FP7-health, grant agreement number 305147; FP7/2012-2017) and by the Instituto de Salud Carlos III (ISCIII) (grant numbers ICI14/00242, PI16/01321, and PI19/01710), co-funded by European Regional Development Fund (ERDF), a way to build Europe. Also, this work was partly supported by the SLT002/16/00183 grant, from the Department of Health of the Generalitat de Catalunya by the call “Acció instrumental de programes de recerca orientats en l’àmbit de la recerca i la innovació en salut”. |
| وصف الملف: | application/pdf |
| تدمد: | 1664-3224 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::267a126441b8f519438038a1e03fd6fa https://doi.org/10.3389/fimmu.2022.924825 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....267a126441b8f519438038a1e03fd6fa |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16643224 |
|---|